TruScreen® ULTRA

The only real-time, objective, primary cervical cancer screening method in the world.

See and Treat - the solution for population based screening in areas where laboratory facilities are scarce.

Extensively proven high accuracy results.
Introduction

TruScreen® ULTRA uses unique real-time electro-optical technology. It provides a direct means of tissue differentiation as a primary screening tool in the general population to identify cervical cancer and precancerous changes (CIN).

TruScreen® ULTRA compares the tissue under observation against a database of known physical tissue characteristics to determine if it is precancerous or cancerous in nature.

If abnormal tissue is detected, there is no need to call the patient back for a second or third visit. The patient can be immediately triaged and proceed to colposcopy and/or histology.

Clinical Performance

In a multi-centre study the TruScreen® ULTRA technology was shown to detect cervical cancer precursors with the equivalent sensitivity of a high quality Pap Smear. Later studies further confirmed this.

Receiver Operating Characteristic (ROC) Curve of the TruScreen® ULTRA technology

Meta-Analysis of Data from China

A meta-analysis demonstrating the higher performance of TruScreen® ULTRA technology against cytology taken from clinical trials conducted in China^2,3.

Variances in Sensitivity of the TruScreen® ULTRA technology and Pap Smears

References:
3. 李伟宏, 金松, 张俊霄, 吴小妹, 陈华, 曾蓉蓉, 王丽, 宫颈癌筛查系统与液基细胞学检测在宫颈病变初筛中的研究. 海南医学院学报, 2011
**TruScreen® ULTRA Principles**

TruScreen® ULTRA uses four different lights and three electrodes to send a combination of optical and electrical signals into the tissue so the returning signals can be examined.

**Optical Transport in Squamous Epithelium**

Precancerous changes affect how light is transmitted, reflected and refracted in tissue. Unlike cytology, TruScreen® ULTRA examines cells below the epithelium. Light waves transmitted from the probe tip reach far enough into the tissue to detect changes in the basal and stromal layers.

---

**Electrical Decay Curves**

TruScreen® ULTRA also directs electrical pulses into the tissue and measures the resulting electrical decay curve. Depending on the underlying tissue, the electrical decay curves will differ.
Women Prefer TruScreen® ULTRA

The key to a successful screening program is the willingness of women to present themselves for examination.

TruScreen® ULTRA has demonstrated that it is significantly more acceptable to women than a conventional Pap Smear.

A comparative study between the use of the TruScreen® ULTRA technology and the conventional Pap Smear was performed at the Whittington Hospital in London. This study showed that the TruScreen® ULTRA technology was associated with significantly less pain, pressure and scraping than experienced with the spatula or brushes required to collect cells from the cervix in cytology based screening. Women also strongly preferred access to an immediate result.

- Real-time results - Patients are not lost to follow-up
- No laboratory facilities or trained cytologists needed
- Objective, self-checking procedures ensure consistent and reproducible results
- High accuracy and earlier detection of precancerous lesions
- Women prefer TruScreen® ULTRA over other methods

TruScreen® ULTRA provides doctors and governments with a solution for cervical cancer screening.

- Prefer Pap 16%
- No preference 2%
- Encouraged to attend for screening 82%
- Real-time – no anxiety, no return trip needed
- Less pain or discomfort
- Willing for their next screening to be using the TruScreen® ULTRA technology

info@truscreen.com | New Zealand: Geyser Building, 100 Parnell Road, Parnell, Auckland 1052
www.truscreen.com | Australia: Level 1, 1 Jamison Street, Sydney, NSW 2000
+61 9091 7475 | United Kingdom: 1 Adam Street, London WC2N6LE